{"id":1068161,"date":"2021-05-26T01:51:33","date_gmt":"2021-05-26T05:51:33","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/travere-therapeutics-provides-regulatory-update-on-sparsentan-development-program-for-focal-segmental-glomerulosclerosis\/"},"modified":"2024-08-18T11:43:45","modified_gmt":"2024-08-18T15:43:45","slug":"travere-therapeutics-provides-regulatory-update-on-sparsentan-development-program-for-focal-segmental-glomerulosclerosis","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/travere-therapeutics-provides-regulatory-update-on-sparsentan-development-program-for-focal-segmental-glomerulosclerosis.php","title":{"rendered":"Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis"},"content":{"rendered":"<p><![CDATA[Conference call and webcast to be held at 4:30p.m. ET Conference call and webcast to be held at 4:30p.m. ET]]><\/p>\n<p>Read more from the original source:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/05\/25\/2235901\/0\/en\/Travere-Therapeutics-Provides-Regulatory-Update-on-Sparsentan-Development-Program-for-Focal-Segmental-Glomerulosclerosis.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis\">Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more from the original source: Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/travere-therapeutics-provides-regulatory-update-on-sparsentan-development-program-for-focal-segmental-glomerulosclerosis.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068161","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068161"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068161"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068161\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}